Eli Lilly & Co.’s bid to expand Cyramza’s (ramucirumab) metastatic lung cancer indication to the first-line setting is facing pushback from the US Food and Drug Administration over the lack of a survival benefit to date and increased toxicity seen in the pivotal RELAY trial.
On 26 February, the Oncologic Drugs Advisory Committee will review Lilly’s supplemental biologics license application for use of ramucirumab, in...





